ClinicalTrials.gg
Not yet recruitingNCT07716995OSA/MAFLDUpdated Nov 2, 2026

Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea

An observational study in Obstructive Sleep Apnea and Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Assiut University · Observational

How we know

Updated Nov 2, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
127
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Sleep Apnea, Obstructive · Assiut University.

Planned enrollment
Largest of 11
127 · median 80
Started
2026
with 3 others
Observational
11 of 13
6 open now
Registered
12th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Assiut University, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2026, is one of 11 observational ones, and was the 12th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

7 of the 13 studies in Sleep Apnea, Obstructive by Assiut University are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Assiut University, or all of them as a file.
02

Study summary

Association between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea

Read the detailed description

Obstructive sleep apnea (OSA) is an increasingly common disorder that is characterized by periodic collapse of the upper airway resulting in cycles of hypoxia and reoxygenation known as chronic intermittent hypoxia(CIH). Evidence has shown that OSA can contribute to the development of many metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia, and the metabolic syndrome).

Metabolic associated fatty liver disease (MAFLD) has become more common in recent years. MAFLD is thought to be the primary cause of chronic liver disorders, and it has grown to be a significant global public health concern. The prevalence of MAFLD has been steadily rising due to changes in lifestyle and dietary patterns, making it the most common chronic liver ailment globally. The global prevalence of MAFLD is 30.1%.

Evidence emerged that linked OSA severity with the development and progression of MAFLD. For example, CIH (a hallmark of OSA) was identified as an independent risk factor in the onset and progression of MAFLD. The essential links between CIH and MAFLD involve insulin resistance, glucose dysregulation, dysfunction of key steps in hepatic lipid metabolism, oxidative stress, and hepatic steatosis and fibrosis, which together indicate that metabolic dysfunction plays a significant role in the pathogenesis of CIH-associated MAFLD

03

Conditions studied

  • Obstructive Sleep Apnea
  • Metabolic Dysfunction-Associated Steatotic Liver Disease
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

  • Patients with a clinical suspicion of sleep-disordered breathing will undergo overnight polysomnography and the followings indices will be recorded(apnea-hypopnea index (AHI); oxygen desaturation index (ODI); lowest arterial oxyhemoglobin saturation during sleep(LaSO2); mean arterial oxyhemoglobin saturation during sleep(mean SpO2); and %sleep time in which SpO2 \< 90%.( TS90%).
  • Diagnosis of MAFLD will made when a patient has BMI >25 kg/m2, T2DM or at least two metabolic risk abnormalities.
  • All patients will undergo data pertaining to clinical history (name, age, sex, residence, occupation, co-morbidities… diabetes, hyperlipidemia, hypertension, ischemic heart disease, special habits; such as alcohol intake and smoking).
  • Four anthropometric measurements will be obtained (height, weight, body mass index, waist circumference (WC)).
  • Blood samples will be collected for doing liver function tests, lipid profile, CBC, HbA1c.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged >18 years old
  • presented with a clinical suspicion of sleep-disordered breathing, including snoring, sleepiness and witnessed sleep apnea

Exclusion criteria

Exclusion Criteria:

  • Patients aged ≤18 years old
  • Pregnancy
  • Presence of
  • Type I DM
  • Patients with fatty liver who undergone bariatric surgeries.
  • Patients with Central sleep apnea, upper airway resistance and narcolepsy
  • Patients with lung diseases with hypoxia
  • Previous history of alcohol consumption, , proton pump inhibitors, antibiotics, and pills
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
127 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Correlation Between Apnea-Hypopnea Index and MASLD

    To assess the correlation between the Apnea-Hypopnea Index (AHI), measured by overnight polysomnography (events/hour), and hepatic steatosis measured by FibroScan with Controlled Attenuation Parameter (CAP), reported in decibels per meter (dB/m).

    Time frame: At baseline

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 2 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Dec 2026 and primary completion Sep 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 21, 2026
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Feb 1, 2027was Sep 2026
CompletionEst.
Sep 1, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2026
Nov 2, 2026
Primary completion
Sep 1, 2026→Feb 1, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Aug 1, 2026→Dec 1, 2026
    Primary completion Sep 1, 2026→Feb 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07716995
Lead sponsor
Assiut University
Responsible party
Amira Mohammed Abdel Mowgod (Clinical Lecturer of Tropical Medicine and Gastroenterology, Assiut University) — Principal investigator
First posted
Jul 21, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Amira Mohamed Abdelmawgod, MD, Assuit University
Contact
amiramohmad60@gmail.com
+201012760437

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion